

Nonaspirin NSAIDs Tied to Lower Breast Ca Risk

BY DIANA MAHONEY
New England Bureau

BOSTON — Long-term use of non-steroidal anti-inflammatory drugs other than aspirin may significantly reduce breast cancer risk in African American and Caucasian women, according to data from a multiethnic study.

Among women overall, however, no associations were seen between breast cancer risk and the use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), Jasmeet Gill, Ph.D., reported at the annual international conference of the American Association for Cancer Research.

Previous studies looking at NSAID use and breast cancer have yielded mixed results, said Dr. Gill, a postdoctoral fellow at the University of Hawaii, Honolulu. "Although the relationship between cyclooxygenase-2 expression and breast cancer has been shown to be biologically plausible, the use of NSAIDs to reduce the risk of breast cancer is not well established," she said.

Dr. Gill and her colleagues identified 4,010 incident breast cancer cases among

American women who participated in the University of Hawaii/University of Southern California Multiethnic Cohort Study from 1993 to 2002, and reviewed NSAID exposure data gleaned from a self-administered questionnaire completed at baseline. The study includes African Americans, Caucasians, Japanese, native Hawaiians, and Hispanics from Hawaii and Los Angeles County.

Cox regression analyses showed no association overall between breast cancer

risk and duration of aspirin use, other NSAID use for 6 or more years, or total NSAID use for 11 or more years. Neither were there consistent associations between medication use and breast cancer risk across strata of ethnicity, body mass index, tumor stage, or patient age, Dr. Gill reported in a poster presentation.

"The only associations observed were for other NSAID use among African American and Caucasian women," she said. The use of NSAIDs other than aspirin

for 6 or more years was associated with a 54% reduction in breast cancer risk among African American women and a 31% reduction in risk among Caucasian women.

"It is unclear why aspirin use was not associated with breast cancer risk reduction as has been shown in other studies, although we are intrigued by the reduced risk associated with other NSAID use in African American and Caucasian women," Dr. Gill said. She had no financial disclosures related to her presentation. ■

Five Predictors Of Successful Cephalic Version

RENO, NEV. — Five key factors predicted successful external cephalic version in a meta-analysis of 43 primary articles describing 8,089 cases, reported Dr. Marjolein Kok at the annual meeting of the Society for Gynecologic Investigation.

Predictors of success, in order, included the following:

- ▶ Uterine relaxation (odds ratio 19; 95% confidence interval 3.1-3.9).
- ▶ Nonengagement (OR 10; CI 6.6-15).
- ▶ Palpable fetal head (OR 9.4; CI 6.0-15).
- ▶ Multiparity (OR 3.5; CI 3.1-3.9).
- ▶ Maternal weight less than 65 kg (OR 1.8; CI 1.2-2.6).

Most studies included in the review were prospective cohort studies, said Dr. Kok in an interview at the meeting, where she presented her findings in poster form.

Studies were reviewed from Medline, Embase, Cochrane Library, and manual searching of bibliographies of known primary and review articles. Articles were included if they reported on both potential clinical prognosticators and external cephalic version success rates.

The final conclusions not only illuminated factors associated with success but offer a way to weigh the importance of each factor. For example, a relaxed uterus is 20 times more likely to predict success, making it a more important prognostic variable than maternal weight.

Dr. Kok, an obstetrician and registrar at the Academic Medical Center in Amsterdam, was assisted in the study by colleagues in the ob.gyn. department at her institution and by Dr. Ben Willem Mol of Maxima Medical Centre Veldhoven in the Netherlands.

—Betsy Bates

Available

FOSAMAX PLUS D
(alendronate sodium/cholecalciferol) tablets

70 mg
5600 IU

fosamaxplusd.com

FOSAMAX PLUS D is a trademark of Merck & Co., Inc.
 MERCK Copyright ©2007 Merck & Co., Inc. All rights reserved. 20704833(1)-FOS